Tirzepatide 20mg or 60mg — Research Compound

Dosing of Tirzepatide varies widely, but common doses include:

• 2.5-5mg/wk (20mg vial suggested)
• 7.5mg-15mg/wk (60mg vial suggested: Best Value)

Tirzepatide is a synthetic peptide commonly referenced in metabolic and endocrine research as a dual GIP/GLP-1 receptor agonist. It is used in controlled study settings evaluating incretin signaling, glucose-regulation pathways, and broader energy-balance models, where protocol-driven measurement and repeatable experimental conditions are essential.

What does that mean in plain English?

As a dual GIP and GLP-1 receptor agonist, Tirzepatide improves blood sugar control, reduces appetite, and significantly lowers body weight, often outperforming single-agonist treatments.

In research, tirzepatide is mainly used to study how activating two key “metabolic messaging” receptors (GIP + GLP-1) can influence things like appetite-related signaling, insulin response, and blood-sugar biomarkers—typically in preclinical or clinical research contexts, not as a consumer-use product.

Specifications:

• Compound: Tirzepatide
• Strength: 60mg or 20mg
• Format: Research compound
• Use: Research use only